Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Antibe Therapeutics Inc(Pre-Merger)
ATBPF
Healthcare
Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,...
otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (OTCID:ATBPF)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(14)
•••
Antler1
X
Post by
Antler1
on Apr 05, 2024 5:22pm
Big bid at 25.5
Fill'r up boys so I can get on with my buy, hold, and wait!! This is a good pick! $ATE
(17)
•••
mstrmnds
X
Post by
mstrmnds
on Apr 05, 2024 4:29pm
Likely Outcome
2 parts: 1. FDA - either 1) financing related or 2) more information ie. PK/PD data submission Conclusion: Time-dependent outcome 2. Financing - either 1) drag-on legal strategy 2) payout Nuance
...more
(4)
•••
FesticleShwartz
X
Comment by
FesticleShwartz
on Apr 05, 2024 1:05pm
RE:Is It Payday Friday?
Spam
(33)
•••
Inthepez
X
Comment by
Inthepez
on Apr 05, 2024 11:14am
RE:RE:Becareful! risky stock
Hey look it's another dumpster account made yesterday... you get bet on dumpster to change his tune when he's penny flipping...telegraphing a mile away. LOL
(1566)
•••
Duster340
X
Post by
Duster340
on Apr 05, 2024 9:29am
Is It Payday Friday?
over at the antibe office haha, maybe the plan is just to play it out until they run out of cards. they are in a pickle and there hands are tied with about 20M in the bank and a cash burn of
...more
(0)
•••
Bobloblaw2
X
Comment by
Bobloblaw2
on Apr 04, 2024 8:38pm
RE:Becareful! risky stock
There won't be a P2 trial if the funding is put on hold due to the Nuance law suit until the matter is settled. And I don't think the FDA clinical hold has as much to do with the science but
...more
(128)
•••
MrMugsy
X
Comment by
MrMugsy
on Apr 04, 2024 8:00pm
RE:Mugsy
hahaha - love it !!!! same old comments - no creativity.
(1566)
•••
Duster340
X
Post by
Duster340
on Apr 04, 2024 2:24pm
Speculation
could be there is something in the science the FDA is not satified with that requires more testing before P2. oops this would be a major set back and puts the final nail in the coffin.
(1566)
•••
Duster340
X
Post by
Duster340
on Apr 04, 2024 2:00pm
Becareful! risky stock
we still are waiting for answers , nothing new since the news release on apr/1st April 1, 2024 Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance Antibe
...more
(13)
•••
Ryeman40
X
Post by
Ryeman40
on Apr 04, 2024 1:44pm
Reformulation
To think this has nothing to do with money (nuance) or trial design (Stauffer). FDA wants more info on new drug which is typical before they start the trial and why its more safer than the last one
...more
(15)
•••
SimonSaysLues
X
Post by
SimonSaysLues
on Apr 04, 2024 7:01am
Mugsy
Next time you look in front of a mirror, say hi to Dan.
(3)
•••
Chianchin
X
Comment by
Chianchin
on Apr 03, 2024 11:54pm
RE:RE:Mugsy
What ever Mugsy buy you all better short it as I have never met a bad investor as mugsy. He/she also bought GUD at $10 ten years ago not GUD $5.50. The simple facts
(128)
•••
MrMugsy
X
Comment by
MrMugsy
on Apr 03, 2024 11:24pm
RE:Mugsy
Oh I'm here. But rather than cry over what's happening, I'm trying to understand it. There's nothing I can say that will help you through your pain - you wouldn't believe it
...more
(15)
•••
SimonSaysLues
X
Post by
SimonSaysLues
on Apr 03, 2024 3:15pm
This volume is only 4 or five people daytrading
It is no sign of support. I myself made 2 buys and 2 sells representing 1/4 of today's volume.
(1566)
•••
Duster340
X
Comment by
Duster340
on Apr 03, 2024 2:27pm
RE:Commercial vs. Science
The issue is they have no money to go forward with P2. as far as we know the science is good only the test results will prove or disprove. nuance wants there money, they won arbitration, that should
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Podcasts